Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

209.99 -0.41 (-0.19%)
Streaming Delayed Price Updated: 10:00 AM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook 
Via MarketBeat
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier
AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while full-year earnings guidance was raised. 
Via Benzinga
AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic
For the full year, the company raised its adjusted and diluted earnings per share guidance to $11.88 to $12.08, up from its previous guidance of $11.67 to $11.87. 
Via Stocktwits
Topics Intellectual Property
AbbVie Inc (NYSE:ABBV) Beats Q2 2025 Earnings and Revenue Estimates, Raises Full-Year Guidance
AbbVie beats Q2 2025 revenue and EPS estimates, raises full-year outlook. Stock surges 4.59% pre-market on strong portfolio performance and pipeline progress. 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
A Peek at AbbVie's Future Earnings
 
Via Benzinga
Looking Into AbbVie's Recent Short Interest
 
Via Benzinga
AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above... 
Via StockStory
AbbVie Retail Traders Remain Wary Amid Report Of $1B Gilgamesh Deal To Boost Mental Health Pipeline
The potential acquisition follows a 2023 licensing partnership between the two companies and comes after Gilgamesh reported promising trial results for its depression drug, GM-2505. 
Via Stocktwits
Topics Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive. 
Via The Motley Fool
Topics Intellectual Property
AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Thursday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock
Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after... 
Via Stocktwits
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile. 
Via Benzinga
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors. 
Via The Motley Fool
Topics Intellectual Property
3 Value Stocks with Questionable Fundamentals
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
The Smartest Dividend Stocks to Buy With $350 Right Now
These stocks offer juicy dividends, solid growth prospects, and stability. 
Via The Motley Fool
The 3 Things That Matter for AbbVie Now
Via The Motley Fool
Topics Intellectual Property
Uber, Western Union, Live Nation Entertainment And A Health Care Stock On CNBC's 'Final Trades'
Analysts and investors are closely watching earnings from AbbVie, Uber, and Western Union to gain insights on market trends. AbbVie expected to see breakout on July 31. 
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
Via The Motley Fool
My Top 2 Earnings Picks For This Earnings Season
 
Via Benzinga
1 Unpopular Stock that Deserves Some Love and 2 to Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
The Smartest Dividend Stocks to Buy With $300 Right Now
Via The Motley Fool
Topics Energy Government World Trade
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'
The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential... 
Via Benzinga
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong. 
Via The Motley Fool
Topics Intellectual Property
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. 
Via Stocktwits
Topics Product Recall
< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.